Should Diagnosis Drive Development of Psychotropic Drugs?

By Davidson, Michael; Lecrubier, Yves | Clinical Psychiatry News, April 2007 | Go to article overview

Should Diagnosis Drive Development of Psychotropic Drugs?


Davidson, Michael, Lecrubier, Yves, Clinical Psychiatry News


Mental illness does not fit distinct phenotypes.

The idea that a diagnostic system can support drug development started with the transition from the Diagnostic and Statistical Manual of Mental Disorders (DSM) I-II to DSM III-IV. We rejected a system based on explanatory dynamics and adopted one based on phenotypic similarities. Our hope was that the new system would reduce biologic, genetic, and pathophysiologic variability. By narrowing phenotypes, we aspired to match biologic targets to pharmacologic solutions.

For a diagnostic system based on phenotype to yield a biologically explainable system, however, three assumptions must be valid. The first is that psychiatric illnesses are real elements and not convenience-driven, man-made categories.

Second, we assume we can categorize mental illness into distinct, well-defined phenotypes. We presume that conditions don't overlap, that there are real points of neutrality between schizophrenia, dissociative disorder, and bipolar disorder. Third, and most important, is the assumption that distinct, well-defined phenotypes are caused by distinct, well-defined phenomena.

Is it possible to categorize psychiatric illnesses into distinct phenotypes? I think not.

Phenotypic categorization uses nonobservational, unverifiable information. I interview the patient or the family. There is no way to verify what they tell me, and I am subjective in my interpretation. Even trained observers vary in how they score observable information. Psychiatric diagnosis is contextual and judgmental.

As for distinct phenotypes, most known risk factors apply to multiple disorders. Socioeconomic status, stress, immigration, and cannabis abuse are risk factors for schizophrenia, depression, substance abuse, and personality disorders.

The main benefit of switching to a phenotypic system was to facilitate communication among mental health professionals. What I call schizophrenia in the United States is what people call schizophrenia in Japan. That doesn't say anything about the validity of our terms.

Likewise, its reliance on phenotype does not necessarily aid drug development. Biologic markers reduce the biologic variability of the phenotype, so that clinical trials can recruit the most homogenetic cohort, objectively assess a drug's effects, and help clarify its mechanism of action.

The paradox of modern drug development is that trials provide evidence of efficacy and safety at usual doses in a general population. In clinical practice, we use much lower or higher doses to treat individuals who vary widely in their response to drug therapy.

Historically, the Food and Drug Administration approved psychotropic drugs for a diagnosis or a syndrome. It has revised its approach, however, so that drugs are indicated for well-defined aspects of a disease or syndrome if supported by valid trials. For example, olanzapine and ziprasidone IM were approved for agitation in schizophrenia and clozapine for suicidality in schizophrenia. The FDA also accepts claims for nonspecific symptoms that present across diseases. Pain and fever are the best examples.

We don't have to change the clinical classification system, but we should look differently at the classification of psychotropic drugs. I would probably begin by targeting what are called today endophenotypes. You have a better chance of succeeding if you target the biologic process of hallucination than if you target the social and biologic complexity in schizophrenia.

DR. DAVIDSON is director of psychiatry at Sheba Medical Center and chairman and professor of psychiatry at the Sackler School of Medicine in Tel Aviv.

MICHAEL DAVIDSON, M.D.

Targeting phenotypes has not led to new drugs. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Should Diagnosis Drive Development of Psychotropic Drugs?
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.